Other Content

Future Events

COVID-19: re-vaccination and variant ...

Part of the ISAC COVID-19 webinar series. 26 September 2022 at 12.00 GMT.

Read more
Antimicrobial Pharmacometrics in ...

This is the second talk in the series of webinars on "When pharmacometrics and systems pharmacology meet infectious disease" organised ...

Read more
32nd International Congress of ...

REGISTER NOW to attend the 32nd International Congress of Antimicrobial Chemotherapy (ICC) in Perth, Australia (27 - 30 November ...

Register here
Publishing Tips & Tricks

Collaboration with Elsevier. Date to be confirmed.

Read More

Part of the ISAC COVID-19 webinar series


COVID-19 has affected 620 million people and been the cause of death for more than 6.5 million already. Its activity continues throughout the world with approximately 1,000.000 new cases per day despite the precautions to stop the pandemic.

At the beginning, masks, social distancing and hand hygiene were the main tools used to stop the pandemic and we urgently learned how to diagnose COVID-19 fast and treat it appropriately. Then, effective vaccines against SARS-CoV-2 were developed.

Vaccination against COVID-19 has saved millions of lives so far. But there are many problems implementing worldwide vaccination such as production, distribution, cost and vaccine hesitancy issues. Beyond that, at this stage of the pandemic, the world must decide:

• Do we need booster doses?
• Are original vaccines effective or do we need variant vaccines?
• What are those variant vaccines?

Experts in the field will answer these timely and important questions in the next webinar in ISAC’s COVID-19 series on 26 September 2022 at 12.00 (GMT).


Rafael Araos (Research Professor, Institute of Science and Innovation in Medicine, Universidad del Desarrollo, Chile)
Rafael Araos is a physician scientist trained in internal medicine and infectious diseases. He is interested in understanding the transmission dynamics of infectious diseases and evaluating the impact of health interventions. During the COVID-19 pandemic, his group built up a population-based, electronic cohort that has allowed them to determine COVID-19 vaccine effectiveness in the real-world setting.

Eric Gao (Medical Affairs Director, Sinocav Biotect Ltd, China)
Yongjun (Eric) Gao is currently the Medical Affairs Director at Sinovac. Prior to that, he was the China lead of epidemiology and health economics at Sanofi Pasteur and the Medical Science team lead at Pfizer vaccine. Before joining the industry, he was the director of the office for public hazards emergency response and the senior medical epidemiologist at China CDC for over 10 years. He graduated from Shandong Medical University. His focus includes infectious diseases, vaccinology and immunology. He is an experienced medical epidemiologist with a demonstrated performance history in public health.

Shanti Pather (Senior Director, Global Medical Affairs, BioNTech, Germany)
Shanti Pather heads the Global Medical Affairs department at BioNTech SE, the manufacturer and developer of the world’s first COVID-19 vaccine and first approved mRNA vaccine, BNT162b2.
Her responsibilities include providing strategic guidance on early-stage clinical development, late-stage clinical data and real world evidence generation, championing global medical education initiatives, as well as leading the global medical strategy in Infectious Diseases.
Prior to joining BioNTech, Shanti held various leadership roles in the pharmaceutical and biotechnology industry from an affiliate, regional and global level, in infectious diseases, rare diseases, neuroscience and oncology.
Shanti has more than 15 years’ experience in Global Medical Affairs including launches in HIV, hepatitis B, diabetes, oncology, dermatology and neurology.

Bárbara Emoingt Furtado (Associated Medical Director for Vaccine & Immune Therapies, AstraZeneca, UK)
Dr Bárbara Furtado graduated as a medical doctor at the Federal University of Rio de Janeiro, Brazil, having specialised in Pediatrics and Pediatric Onco-Hematology at two prestigious institutions in Rio de Janeiro. She joined the pharmaceutical industry in 2012, and since 2016 she has been dedicated to the area of Medical Affairs for Vaccination. During this period, she has participated in the publication of four articles and a book chapter. She is currently Associate Medical Director International for Vaccines and Immunotherapy at AstraZeneca.